Host Paul Raeburn interviews Dr. Steven Nissen, chair of cardiovascular medicine at the Cleveland Clinic, at the American College of Cardiology 2008 Conference in Chicago. Dr. Nissen shares his thoughts on results from the PERISCOPE study, which measured the comparative potential for cardiovascular benefits of an insulin secretion promoter, glimepiride, and insulin sensitizer, pioglitazone. The central question: Does it matter how you lower blood sugar?
Cardiology Update from the 2008 ACC Annual Meeting
Share
SaveShare this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Overview
Recommended
Details
Presenters
Overview
Host Paul Raeburn interviews Dr. Steven Nissen, chair of cardiovascular medicine at the Cleveland Clinic, at the American College of Cardiology 2008 Conference in Chicago. Dr. Nissen shares his thoughts on results from the PERISCOPE study, which measured the comparative potential for cardiovascular benefits of an insulin secretion promoter, glimepiride, and insulin sensitizer, pioglitazone. The central question: Does it matter how you lower blood sugar?
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?